[Characteristics of the effects of de-nol on the course of erosive-ulcerative lesions of the esophagus, stomach and duodenum associated with Helicobacter pylori].
Grebenev
A L
AL
Miagkova
L P
LP
Golochevskaia
V S
VS
Lapina
T L
TL
Sklianskaia
O A
OA
D000863:Antacids / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000188:drug therapy; D004382:Duodenitis / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D005756:Gastritis / Q000188:drug therapy; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy*; D013276:Stomach Ulcer / Q000188:drug therapy; D013997:Time Factors
D000863:Antacids; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; C002791:bismuth tripotassium dicitrate; D001729:Bismuth